Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

UBXG vs ABVX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UBXG Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 4–4 Matrix Metrics)

UBXG Overall Winner 6-Pillar Tally: UBXG 3 – 1 ABVX (2 Tie) Matrix Metrics: UBXG 4 – 4 ABVX

As of Nov 20, 2026, U-BX Technology Ltd. (UBXG) is the stronger overall head-to-head candidate over Abivax SA (ABVX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UBXG carries a Unified Composite Score of 48.9/100 (HOLD) at $5.03 (N/M Forward P/E, -87.6% operating margin), whereas ABVX carries 42.4/100 (HOLD) at $73.20 (N/M Forward P/E, -6270.4% operating margin).

  • Growth vs. Quality Trade-Off: UBXG earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. ABVX 42.4/100 HOLD) and 10.23β · 225% Vol risk profile, whereas ABVX leads top-line expansion (-6.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: UBXG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.9); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UBXG vs ABVX
UBXG NASDAQ Head-to-Head Winner
U-BX Technology Ltd. Ordinary Shares
Services-Computer Programming, Data Processing, Etc.
$5.03
-0.2% 1D
Market Cap $9.2M
TTM Revenue $24M
Forward P/E N/M
Beta / 30D Vol 10.23β · 225% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.9 · SMA20: $5.96 · SMA50: $4.05
ABVX NASDAQ
Abivax SA American Depositary Shares
Pharmaceutical Preparations
$73.20
-9.24% 1D
Market Cap $7.1B
TTM Revenue $4.7M
Forward P/E N/M
Beta / 30D Vol 1.55β · 55% Vol
Unified Composite Score
42.4 / 100 HOLD
Tech 25.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 30
RSI-14: 30.0 · SMA20: $86.08 · SMA50: $91.16

6-Pillar Scorecard Institutional Category Breakdown (UBXG 3 – 1 ABVX)

Columns: Metric · UBXG · ABVX
1. Valuation Multiples UBXG
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.4x N/M
2. Growth & Scale ABVX
Revenue Growth (YoY) -32.6% -6.8%
Earnings Growth (YoY) -88.4% +0.0%
TTM Revenue (USD) $24M $4.7M
Market Cap $9.2M $7.1B
3. Profitability & Quality UBXG
Gross Margin 0.3% 100.0%
Operating Margin -87.6% -6270.4%
Net Profit Margin -55.1% 0.0%
Return on Equity (ROE) -46.6% -252.3%
4. Balance Sheet & Cash Flow UBXG
Cash Generation (TTM) -$13M EBITDA -$292M EBITDA
Cash Flow Margin -53.4% EBITDA Mgn N/A
Net Cash / Leverage $30.52 Book/Sh · -46.6% ROE $5.16 Book/Sh · -252.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 76.9% (<1st %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Advertising Agencies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UBXG (4) vs ABVX (4)
Institutional Metric UBXG ABVX Criterion Row Edge
Market Capitalization
Scale
$9.2M $7.1B Larger Scale ABVX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-32.6% -6.8% Higher Growth ABVX
Operating Margin (TTM)
Profitability
-87.6% -6270.4% Higher Margin UBXG
Net Profit Margin
Profitability
-55.1% 0.0% Higher Margin ABVX
Return on Equity (ROE)
Capital Efficiency
-46.6% -252.3% Higher ROE UBXG
52-Week Range Position
Momentum
38% ($0–$13) 12% ($63–$149) Stronger Trend UBXG
Beta / 30D Volatility
Risk Regime
10.23β · 225% Vol 1.55β · 55% Vol Lower Realized Risk ABVX
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 42.4 / 100 (HOLD) Higher Composite UBXG
Trailing 12M Revenue (USD)
Operating Scale
$24M $4.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.3% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$13M EBITDA ($30.52 Book/Sh · -46.6% ROE) -$292M EBITDA ($5.16 Book/Sh · -252.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABVX +88.29 pp
UBXG: -48.14% · ABVX: +40.15%
3M Horizon UBXG +367.47 pp
UBXG: +379.05% · ABVX: +11.58%
6M Horizon UBXG +149.97 pp
UBXG: +159.28% · ABVX: +9.31%
1Y Horizon UBXG +128.03 pp
UBXG: +149.01% · ABVX: +20.98%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UBXG vs ABVX. Trailing 12-month operating profitability (UBXG -87.6% vs ABVX -6270.4%) and valuation multiples (UBXG N/M vs ABVX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

UBXG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$24M
Gross Margin0.3%
Op. Margin-87.6%
ROE / Fwd P/E-46.6% · N/M
ABVX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.7M
Gross Margin100.0%
Op. Margin-6270.4%
ROE / Fwd P/E-252.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UBXG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UBXG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.9%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UBXG Moat Profile Cyclical / Execution-Driven Positioning
Advertising Agencies Operator
Competes within the Advertising Agencies value chain with $9.2M market capitalization and -87.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.1B market capitalization and -6270.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ UBXG vs ABVX Key Questions & Quantitative Answers

As of Nov 20, 2026, U-BX Technology Ltd. (UBXG) is the stronger overall head-to-head candidate over Abivax SA (ABVX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UBXG carries a Unified Composite Score of 48.9/100 (HOLD) at $5.03 (N/M Forward P/E, -87.6% operating margin), whereas ABVX carries 42.4/100 (HOLD) at $73.20 (N/M Forward P/E, -6270.4% operating margin). Growth vs. Quality Trade-Off: UBXG earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. ABVX 42.4/100 HOLD) and 10.23β · 225% Vol risk profile, whereas ABVX leads top-line expansion (-6.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: UBXG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.9); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVX leads the Growth & Scale pillar: UBXG posts -32.6% YoY revenue growth and -88.4% YoY earnings growth on $24M TTM revenue (0.3% gross margin, -87.6% operating margin), compared with ABVX at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (100.0% gross margin, -6270.4% operating margin). On trailing 12-month operating scale, UBXG generates $24M in USD-normalized revenue versus $4.7M for ABVX. In operating R&D and SG&A reinvestment, UBXG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVX.

UBXG screens cheaper on headline valuation multiples. UBXG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-53.4% EBITDA margin), whereas ABVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UBXG (-46.6% ROE) versus ABVX (-252.3% ROE) capital efficiency.

In options market volatility and institutional positioning, UBXG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (10.23β · 225% Vol realized risk). By comparison, ABVX carries 76.9% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.